Tokyo Tape
Sign in
← Koa Shoji Holdings

Half-year report · HY

9273.TEDINET S100XK39
Period2025-07-01 → 2025-12-31
Filed2026-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥12.7bn2025-07-01 → 2025-12-31Cons.Net sales
Revenue¥23.3bn2024-07-01 → 2025-06-30Cons.Net sales (5-year summary)
Revenue¥12.3bn2024-07-01 → 2024-12-31Cons.Net sales
Operating income¥3.2bn2025-07-01 → 2025-12-31Cons.Operating income
Operating income¥3.1bn2024-07-01 → 2024-12-31Cons.Operating income
Ordinary income¥3.1bn2025-07-01 → 2025-12-31Cons.Ordinary income
Ordinary income¥5.4bn2024-07-01 → 2025-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.1bn2024-07-01 → 2024-12-31Cons.Ordinary income
Profit before tax¥3.1bn2025-07-01 → 2025-12-31Cons.Income before income taxes
Profit before tax¥3.1bn2024-07-01 → 2024-12-31Cons.Income before income taxes
Net income (owners)¥2.1bn2025-07-01 → 2025-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.6bn2024-07-01 → 2025-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.0bn2024-07-01 → 2024-12-31Cons.Profit loss attributable to owners of parent
Net income¥2.1bn2025-07-01 → 2025-12-31Cons.Profit loss
Net income¥2.0bn2024-07-01 → 2024-12-31Cons.Profit loss
Total assets¥36.5bnat 2025-12-31Cons.Assets
Total assets¥36.1bnat 2025-06-30Cons.Assets
Total assets¥33.6bnat 2024-12-31Cons.Total assets (5-year summary)
Total liabilities¥7.0bnat 2025-12-31Cons.Liabilities
Total liabilities¥8.0bnat 2025-06-30Cons.Liabilities
Net assets / equity¥29.6bnat 2025-12-31Cons.Net assets
Net assets / equity¥28.1bnat 2025-06-30Cons.Net assets
Net assets / equity¥26.6bnat 2024-12-31Cons.Net assets (5-year summary)
Cash and deposits¥13.2bnat 2025-12-31Cons.Cash and deposits
Cash and deposits¥14.9bnat 2025-06-30Cons.Cash and deposits
Cash & equivalents¥13.0bnat 2025-12-31Cons.Cash and cash equivalents
Cash & equivalents¥14.7bnat 2025-06-30Cons.Cash and cash equivalents
Cash & equivalents¥9.8bnat 2024-12-31Cons.Cash and cash equivalents
Cash & equivalents¥13.2bnat 2024-06-30vCons.Cash and cash equivalents
Operating cash flow¥360m2025-07-01 → 2025-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥3.8bn2024-07-01 → 2025-06-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.0bn2024-07-01 → 2024-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.3bn2025-07-01 → 2025-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.3bn2024-07-01 → 2025-06-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.7bn2024-07-01 → 2024-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥829m2025-07-01 → 2025-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥939m2024-07-01 → 2025-06-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥738m2024-07-01 → 2024-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥49.532025-07-01 → 2025-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥86.382024-07-01 → 2025-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥48.662024-07-01 → 2024-12-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio80.9%at 2025-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio77.9%at 2025-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio79.1%at 2024-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-07-01 → 2025-12-31−¥649m
Reconciling Itemsreconcilingrevenue intersegment2025-07-01 → 2025-12-31−¥649m
Reconciling Itemsreconcilingsegment profit2025-07-01 → 2025-12-31¥46m
Drug Substance Sales Businessreportable segmentrevenue2025-07-01 → 2025-12-31¥8.5bn
Drug Substance Sales Businessreportable segmentrevenue external2025-07-01 → 2025-12-31¥7.8bn
Drug Substance Sales Businessreportable segmentrevenue intersegment2025-07-01 → 2025-12-31¥649m
Drug Substance Sales Businessreportable segmentsegment profit2025-07-01 → 2025-12-31¥1.8bn
Pharmaceutical Marketing Businessreportable segmentrevenue2025-07-01 → 2025-12-31¥4.8bn
Pharmaceutical Marketing Businessreportable segmentrevenue external2025-07-01 → 2025-12-31¥4.8bn
Pharmaceutical Marketing Businessreportable segmentsegment profit2025-07-01 → 2025-12-31¥1.3bn
—segment totalrevenue2025-07-01 → 2025-12-31¥13.3bn
—segment totalrevenue external2025-07-01 → 2025-12-31¥12.7bn
—segment totalrevenue intersegment2025-07-01 → 2025-12-31¥649m
—segment totalsegment profit2025-07-01 → 2025-12-31¥3.1bn
Reconciling Itemsreconcilingrevenue2024-07-01 → 2024-12-31−¥604m
Reconciling Itemsreconcilingrevenue intersegment2024-07-01 → 2024-12-31−¥604m
Reconciling Itemsreconcilingsegment profit2024-07-01 → 2024-12-31¥81m
Drug Substance Sales Businessreportable segmentrevenue2024-07-01 → 2024-12-31¥8.0bn
Drug Substance Sales Businessreportable segmentrevenue external2024-07-01 → 2024-12-31¥7.4bn
Drug Substance Sales Businessreportable segmentrevenue intersegment2024-07-01 → 2024-12-31¥604m
Drug Substance Sales Businessreportable segmentsegment profit2024-07-01 → 2024-12-31¥1.6bn
Pharmaceutical Marketing Businessreportable segmentrevenue2024-07-01 → 2024-12-31¥4.9bn
Pharmaceutical Marketing Businessreportable segmentrevenue external2024-07-01 → 2024-12-31¥4.9bn
Pharmaceutical Marketing Businessreportable segmentsegment profit2024-07-01 → 2024-12-31¥1.4bn
—segment totalrevenue2024-07-01 → 2024-12-31¥12.9bn
—segment totalrevenue external2024-07-01 → 2024-12-31¥12.3bn
—segment totalrevenue intersegment2024-07-01 → 2024-12-31¥604m
—segment totalsegment profit2024-07-01 → 2024-12-31¥3.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 495
ItemContextValueUnit
Short term loans payablePrior1YearInstant860000000JPY
Short term loans payableInterimInstant860000000JPY
Accounts payable otherPrior1YearInstant361305000JPY
Accounts payable otherInterimInstant270997000JPY
Accounts payable facilitiesPrior1YearInstant1277390000JPY
Accounts payable facilitiesInterimInstant49329000JPY
Current portion of long term loans payablePrior1YearInstant349904000JPY
Current portion of long term loans payableInterimInstant354104000JPY
Income taxes payablePrior1YearInstant1039296000JPY
Income taxes payableInterimInstant1040124000JPY
Provision for bonusesPrior1YearInstant47964000JPY
Provision for bonusesInterimInstant38822000JPY
Other clPrior1YearInstant411420000JPY
Other clInterimInstant359733000JPY
Current liabilitiesPrior1YearInstant6363679000JPY
Current liabilitiesInterimInstant5471535000JPY
Long term loans payablePrior1YearInstant1241480000JPY
Long term loans payableInterimInstant1086328000JPY
Deferred tax liabilitiesPrior1YearInstant7192000JPY
Deferred tax liabilitiesInterimInstant5137000JPY
Provision for directors retirement benefitsPrior1YearInstant162767000JPY
Provision for directors retirement benefitsInterimInstant161109000JPY
Net defined benefit liabilityPrior1YearInstant146049000JPY
Net defined benefit liabilityInterimInstant154034000JPY
Other nclPrior1YearInstant72925000JPY
Other nclInterimInstant85989000JPY
Noncurrent liabilitiesPrior1YearInstant1630414000JPY
Noncurrent liabilitiesInterimInstant1492599000JPY
LiabilitiesPrior1YearInstant7994094000JPY
LiabilitiesInterimInstant6964134000JPY
Capital stockPrior1YearInstant1338752000JPY
Capital stockInterimInstant1338752000JPY
Capital surplusPrior1YearInstant1022303000JPY
Capital surplusInterimInstant1022303000JPY
Retained earningsPrior1YearInstant25733458000JPY
Retained earningsInterimInstant27145559000JPY
Treasury stockPrior1YearInstant-484000JPY
Treasury stockInterimInstant-484000JPY
Shareholders equityPrior1YearInstant28094029000JPY
Shareholders equityInterimInstant29506130000JPY
Valuation difference on available for sale securitiesPrior1YearInstant30798000JPY
Valuation difference on available for sale securitiesInterimInstant48959000JPY
Deferred gains or losses on hedgesPrior1YearInstant-4163000JPY
Deferred gains or losses on hedgesInterimInstant-3336000JPY
Valuation and translation adjustmentsPrior1YearInstant26634000JPY
Valuation and translation adjustmentsInterimInstant45623000JPY
Net assetsPrior1YearInstant28120664000JPY
Net assetsInterimInstant29551753000JPY
Liabilities and net assetsPrior1YearInstant36114758000JPY
Liabilities and net assetsInterimInstant36515888000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2025-06-30pass
balance sheet identityconsolidated 2025-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-06-30pass
statement vs summary · net assetsconsolidated 2025-12-31pass
statement vs summary · net income attributable to parentconsolidated 2024-07-01/2024-12-31pass
statement vs summary · net income attributable to parentconsolidated 2025-07-01/2025-12-31pass
statement vs summary · operating cash flowconsolidated 2024-07-01/2024-12-31pass
statement vs summary · operating cash flowconsolidated 2025-07-01/2025-12-31pass
statement vs summary · revenueconsolidated 2024-07-01/2024-12-31pass
statement vs summary · revenueconsolidated 2025-07-01/2025-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass